
What is claimed is:


1. A compound of Formula (I):



(I),

or a stereoisomer, a geometric isomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, wherein:

each of W_1, W_2 and W_3 is independently N or CR^c;

Z is CN, N_3 or ;

X is H, D, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$heterocyclyl, -$(C_1$-$C_4)$alkylene-$(C_3$-$C_6)$cycloalkyl or -$(C_1$-$C_4)$alkylene-$(C_3$-$C_6)$heterocyclyl, wherein each of the $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$heterocyclyl, -$(C_1$-$C_4)$alkylene-$(C_3$-$C_6)$cycloalkyl and -$(C_1$-$C_4)$alkylene-$(C_3$-$C_6)$heterocyclyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N_3, OR^a, SR^a, NR^aR^b, -C(=O)NR^aR^b, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$haloalkyl, $(C_2$-$C_6)$alkenyl and $(C_2$-$C_6)$alkynyl;

Y is $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_6$-$C_{10})$aryl or 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, wherein each of the $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_6$-$C_{10})$aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N_3, OR^a, SR^a, NR^aR^b, -C(=O)NR^aR^b, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$haloalkyl, $(C_2$-$C_6)$alkynyl, $(C_6$-$C_{10})$aryl and 5-10 membered heteroaryl;

R^1 is H, D, Cl, OR^a, NR^aR^b, $(C_1$-$C_6)$aliphatic or $(C_3$-$C_6)$cycloalkyl, wherein each of the $(C_1$-$C_6)$aliphatic and $(C_3$-$C_6)$cycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N_3, OR^a, SR^a and NR^aR^b, provided that when each of

W_1, W_2 and W_3 is CH, R^1 is not H or NH_2;


each R^a and R^b is independently H, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$heterocyclyl, $(C_6\text{-}C_{10})$aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, -$(C_1\text{-}C_4)$alkylene-$(C_6\text{-}C_{10})$aryl or -$(C_1\text{-}C_4)$alkylene-(5-10 membered heteroaryl); or when R^a and R^b are bonded to the same nitrogen atom, R^a and R^b, together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered heterocyclic ring, wherein each of the $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$heterocyclyl, $(C_6\text{-}C_{10})$aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N_3, OH, NH_2, $(C_1\text{-}C_6)$alkoxy, and $(C_1\text{-}C_6)$alkylamino; and


each R^c is independently H.


2. The compound according to claim 1, wherein each of W_1 and W_2 is independently N or CR^c, W_3 is CR^c.


3. The compound according to claim 1, wherein R^1 is H, D, Cl, CH_3, CH_2CH_3, CF_3, CH_2CF_3, OCH_3, OCH_2CH_3, NH_2, $NHCH_3$ or $N(CH_3)_2$, provided that when each of W_1, W_2 and W_3 is CH, R^1 is not H or NH_2.


4. The compound according to claim 1 having one of the following structures:



(1),



(2),



(3),


























(4),


























(5),




















(6),


(7),


(8),


(9),

(10),

(11),

(12),

(13),

(14),

(15),

(16),

(17),

(18),

(19),

(20),

(21),

(22),

(23),

(24),

(25),

(26),

(27),

(28),

(29),

(30),

(31),

(32),


(33),

(34),

(35),

(36),

(37),

(38),

(39),

(40),

(41),

(42),

(43),

(44),

(45),

(46),

(47),

(48),

(49),

(50),

(51),

(52),

(53),

(54),

(55),

(56),


(57),

(58),

(59),

(60),

(61),

(62),

(63),

(64),

(65),

(66),

(67),

(68),

(69),

(70),

(71),

(72),

(73) or

(74).

5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

6. The pharmaceutical composition according to claim 5, further comprising an additional therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis or a combination thereof.

7. The pharmaceutical composition according to claim 6, wherein the additional therapeutic agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin, ixabepilone, tamoxifen, flutamide, gonadorelin analogues, megestrol, prednidone, dexamethasone, methylprednisolone, thalidomide, interferon alfa, leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, ramucirumab, rituximab, tositumomab, trastuzumab, or a combination thereof.

8. Use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for preventing, managing, treating or lessening the severity of a proliferative disorder, wherein the proliferative disorder is colon cancer, breast cancer, lung cancer, or prostate cancer.